Brii Bio acquires Vir’s antibody rights for Hepatitis B in Greater China
Pharmaceutical Technology
JULY 4, 2022
Given subcutaneously, the antibody can hinder the entry of all ten HBV genotypes into hepatocytes and can also lower virion and subviral particle levels in the blood. A widely neutralising monoclonal antibody (mAb), VIR-3434 (BRII-877) acts on the hepatitis B virus (HBV). The mAb is presently in the Phase II development stage.
Let's personalize your content